Fieldstone Bio recently raised $5 million in seed funding led by Ubiquity Ventures with participation from E14 and LDV ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

IO Biotech's vaccines activate T cells to modify the tumor microenvironment, targeting both cancer and immune-suppressive cells. The T-win technology combines IO102 and IO103, targeting IDO and PD ...

IO Biotech's co-founder presented advancements in cancer vaccines at the 2025 AACR Annual Meeting, highlighting innovative therapeutic strategies. IO Biotech, a clinical-stage biopharmaceutical ...

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

NEW YORK - IO Biotech (IOBT), a clinical-stage biopharmaceutical firm with a market capitalization of approximately $61 million, has presented new preclinical data on two therapeutic cancer vaccine ...

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...